Treatment of severe idiopathic hypoparathyroidism: a case report

Hypoparathyroidism is a rare disorder characterized by parathyroid hormone (PTH) insufficiency, the development of hypocalcemia and alteration of bone tissue remodeling. The goal of treatment is to normalize the indicators of calcium-phosphorus metabolism and leveling of clinical manifestations....

Full description

Bibliographic Details
Main Authors: Diliara Sh. Umiarova, Tatiana A. Grebennikova, Natalya V. Tarbaeva, Zhanna E. Belaya
Format: Article
Language:English
Published: Endocrinology Research Centre 2018-12-01
Series:Остеопороз и остеопатии
Subjects:
Online Access:https://osteo-endojournals.ru/osteo/article/viewFile/9878/7489
_version_ 1818622712029904896
author Diliara Sh. Umiarova
Tatiana A. Grebennikova
Natalya V. Tarbaeva
Zhanna E. Belaya
author_facet Diliara Sh. Umiarova
Tatiana A. Grebennikova
Natalya V. Tarbaeva
Zhanna E. Belaya
author_sort Diliara Sh. Umiarova
collection DOAJ
description Hypoparathyroidism is a rare disorder characterized by parathyroid hormone (PTH) insufficiency, the development of hypocalcemia and alteration of bone tissue remodeling. The goal of treatment is to normalize the indicators of calcium-phosphorus metabolism and leveling of clinical manifestations. Standard treatment of hypoparathyroidism consists of oral calcium and active forms of vitamin D, in doses necessary to maintain calcium levels at the lower limit of the reference interval. Nevertheless, treatment of the disease exerts certain difficulties in clinical practice. At the same time, compensation of the hypoparathyroidism is necessary to prevent ectopic calcification. Daily subcutaneous delivery of PTH (184) and PTH (134) has emerged as a promising therapeutic tool. However, its use should be restricted to patients insufficiently controlled with the standard treatment with active vitamin D and calcium. We present a clinical case of idiopathic hypoparathyroidism with severe clinical presentation of hypocalcaemia and ectopic calcification. Idiopathic hypoparathyroidism is a consequence of autoimmune destruction of the parathyroid glands and is exhibited by excluding all known causes of hypoparathyroidism. PTH (134) treatment allowed reducing the dose of calcium and vitamin D and achieving compensation of the disease.
first_indexed 2024-12-16T18:29:31Z
format Article
id doaj.art-fa8f1c16139943028e2ebd5e33e2a550
institution Directory Open Access Journal
issn 2072-2680
2311-0716
language English
last_indexed 2024-12-16T18:29:31Z
publishDate 2018-12-01
publisher Endocrinology Research Centre
record_format Article
series Остеопороз и остеопатии
spelling doaj.art-fa8f1c16139943028e2ebd5e33e2a5502022-12-21T22:21:20ZengEndocrinology Research CentreОстеопороз и остеопатии2072-26802311-07162018-12-01212364010.14341/osteo98788605Treatment of severe idiopathic hypoparathyroidism: a case reportDiliara Sh. Umiarova0Tatiana A. Grebennikova1Natalya V. Tarbaeva2Zhanna E. Belaya3Endocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreHypoparathyroidism is a rare disorder characterized by parathyroid hormone (PTH) insufficiency, the development of hypocalcemia and alteration of bone tissue remodeling. The goal of treatment is to normalize the indicators of calcium-phosphorus metabolism and leveling of clinical manifestations. Standard treatment of hypoparathyroidism consists of oral calcium and active forms of vitamin D, in doses necessary to maintain calcium levels at the lower limit of the reference interval. Nevertheless, treatment of the disease exerts certain difficulties in clinical practice. At the same time, compensation of the hypoparathyroidism is necessary to prevent ectopic calcification. Daily subcutaneous delivery of PTH (184) and PTH (134) has emerged as a promising therapeutic tool. However, its use should be restricted to patients insufficiently controlled with the standard treatment with active vitamin D and calcium. We present a clinical case of idiopathic hypoparathyroidism with severe clinical presentation of hypocalcaemia and ectopic calcification. Idiopathic hypoparathyroidism is a consequence of autoimmune destruction of the parathyroid glands and is exhibited by excluding all known causes of hypoparathyroidism. PTH (134) treatment allowed reducing the dose of calcium and vitamin D and achieving compensation of the disease.https://osteo-endojournals.ru/osteo/article/viewFile/9878/7489hypoparathyroidismhypocalcaemiahyperphosphatemiaectopic calcificationteriparatideсase report
spellingShingle Diliara Sh. Umiarova
Tatiana A. Grebennikova
Natalya V. Tarbaeva
Zhanna E. Belaya
Treatment of severe idiopathic hypoparathyroidism: a case report
Остеопороз и остеопатии
hypoparathyroidism
hypocalcaemia
hyperphosphatemia
ectopic calcification
teriparatide
сase report
title Treatment of severe idiopathic hypoparathyroidism: a case report
title_full Treatment of severe idiopathic hypoparathyroidism: a case report
title_fullStr Treatment of severe idiopathic hypoparathyroidism: a case report
title_full_unstemmed Treatment of severe idiopathic hypoparathyroidism: a case report
title_short Treatment of severe idiopathic hypoparathyroidism: a case report
title_sort treatment of severe idiopathic hypoparathyroidism a case report
topic hypoparathyroidism
hypocalcaemia
hyperphosphatemia
ectopic calcification
teriparatide
сase report
url https://osteo-endojournals.ru/osteo/article/viewFile/9878/7489
work_keys_str_mv AT diliarashumiarova treatmentofsevereidiopathichypoparathyroidismacasereport
AT tatianaagrebennikova treatmentofsevereidiopathichypoparathyroidismacasereport
AT natalyavtarbaeva treatmentofsevereidiopathichypoparathyroidismacasereport
AT zhannaebelaya treatmentofsevereidiopathichypoparathyroidismacasereport